Dublin, Jan. 03, 2017 -- Research and Markets has announced the addition of the "Acne Vulgaris Forecast in 15 Major Markets 2016-2026" report to their offering.
This report provides the current prevalent population for Acne Vulgaris across 15 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Turkey, Poland, Australia, Japan, China, Brazil and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Acne Vulgaris have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Acne Vulgaris include:
- Underlying hormone imbalance
- Puberty
- Family history
- Skin scarring
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Acne Vulgaris
10. Features of Acne Vulgaris patients
11. Predominant Features of Acne Vulgaris
12. Comorbid Conditions and Features of Acne Vulgaris
13. Scarring in Patients with Acne Vulgaris
14. Location of Acne
15. Patient-Based Offering
16. Online Pricing Data and Platforms
17. References
18. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/g2tng6/acne_vulgaris
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Dermatology


DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Washington Post Publisher Will Lewis Steps Down After Layoffs
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



